Kailera Therapeutics (NASDAQ:KLRA) Upgraded to “Hold” at Wall Street Zen

Kailera Therapeutics (NASDAQ:KLRA) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Kailera Therapeutics Stock Down 10.4%

Shares of KLRA opened at $22.47 on Friday. Kailera Therapeutics has a 12 month low of $22.10 and a 12 month high of $28.23.

Insider Activity at Kailera Therapeutics

In other Kailera Therapeutics news, Director Adam Koppel purchased 1,562,500 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average cost of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares of the company’s stock, valued at $361,332,288. The trade was a 7.43% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. The trade was a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 10,460,938 shares of company stock valued at $167,375,008.